Lyell Immunopharma, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Dr. Jarrad Aguirre, previously SVP of Medical Affairs, was appointed Interim Chief Medical Officer effective May 11, 2026, with annual base salary of $515,000, 50% bonus target, and one-time grant of 15,000 options vesting over four years. If promoted to permanent CMO, compensation remains the same with an additional 47,500 option grant. The letter indicates Lyell was navigating an existing CMO absence at the time of this appointment.
Why this rating
Internal promotion to fill CMO gap; routine leadership transition. Compensation (~$770K annual + equity) is modest relative to $129M market cap; no material business impact signaled.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.